Importance of Achieving DiseaseControl in Adults With Moderate-to-Severe AD
Dermatology
This video features Dr. Eric Simpson's presentation on the importance of achieving diseasecontrol in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about diseasecontrol and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.
Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.
Dr. Ramien explores the concept of disease modification in AD focusing on diseasecontrol, and the prevention or slowing of development of atopic comorbidities.
GOLD 2023 | Clinical Presentation of COPD and Disease Burden
Pulmonology
Dr. Igor Barjaktarevic discusses the diverse clinical aspects of COPD, emphasizing the role of inflammation and the importance of recognizing the heterogeneity of COPD.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.